BiotechTube

ASP8062 + Placebo ASP8062 + buprenorphine/naloxone

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Use Disorder

Conditions

Opioid Use Disorder

Trial Timeline

Nov 8, 2021 → Feb 28, 2023

NCT ID
NCT05062577

About ASP8062 + Placebo ASP8062 + buprenorphine/naloxone

ASP8062 + Placebo ASP8062 + buprenorphine/naloxone is a phase 2 stage product being developed by Astellas Pharma for Opioid Use Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05062577. Target conditions include Opioid Use Disorder.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT05062577Phase 2Withdrawn
NCT04447287Phase 1Completed

Competing Products

20 competing products in Opioid Use Disorder

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
72
SUBLOCADEIndivior PLCPhase 3
72
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
33
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
33
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiApproved
85
NaldemedineShionogiPhase 1/2
41
Naldemedine + PlaceboShionogiPhase 3
77
Placebo + NaldemedineShionogiPhase 2
52
Naldemedine + PlaceboShionogiPhase 3
77
Naldemedine + PlaceboShionogiPhase 2
52
NaloxegolKyowa KirinPre-clinical
23
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
NaloxegolKyowa KirinPre-clinical
23
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
52
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
77
Naloxegol + NaloxegolAstraZenecaPhase 1
33
NKTR-118 + Usual careAstraZenecaPhase 3
77
Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85